Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by kristian7on Nov 05, 2017 3:06pm
466 Views
Post# 26908758

Prometic’s Dr. Raymond Hakim

Prometic’s Dr. Raymond Hakim

Belding H. Scribner Award

RAYMOND M. HAKIM, MD, PHD

The Belding H. Scribner Award will be tendered to Raymond M. Hakim, MD, PhD, on Saturday, Nov. 4, for his career-long contributions to the practice of nephrology. Dr. Hakim is professor of medicine in the division of nephrology and hypertension at the Vanderbilt University Medical Center.

Established in 1995, the Belding H. Scribner Award is presented to individuals who have made outstanding contributions to the care of patients with renal disorders or have substantially influenced the clinical practice of nephrology. Dr. Hakim has made significant contributions in patient care, research, and service to professional organizations. 

Dr. Hakim began his career as an engineer. He received a master of science degree from Rensselaer Polytechnic Institute and a PhD in engineering from the Massachusetts Institute of Technology in 1967. He worked in Montreal as a research engineer at Hydro-Quebec.

He changed his career path to study medicine at McGill University and completed his residency in internal medicine at the Royal Victoria Hospital in 1979. He followed this with a fellowship in nephrology at Harvard Medical School and Brigham and Women’s Hospital.

From 1981 to 1987, he was associate professor of medicine at Harvard and attending nephrologist at Brigham and Women’s Hospital. In 1987, he became professor of medicine at the Vanderbilt University School of Medicine as well as director of clinical services in nephrology and medical director of the dialysis facility at the Vanderbilt University Medical Center.

In 1995, Dr. Hakim was one of the founders and chief medical officer of the Renal Care Group, a provider of outpatient dialysis services. By 2005, the Renal Care Group had more than 35,000 patients and had the lowest mortality and hospitalization rates among all dialysis providers, according to the United States Renal Data System (USRDS). The group merged with Fresenius Medical Care in 2007, and Dr. Hakim became the chief medical officer, serving from 2009 to 2012. His tenure was associated with a 20% reduction in mortality and hospitalization of its patients.

Dr. Hakim has spoken at many patient and health care professional meetings, authored more than 190 articles on clinical and basic research in dialysis and plasmapheresis, and contributed 35 chapters to medical books. He has served as a member of the editorial boards of the American Journal of Kidney Disease, Seminars in Dialysis, and Kidney International.

He chaired several professional committees, including the National Kidney Foundation of Middle Tennessee, USRDS scientific advisory committee, and Renal Physicians Association program planning committee. He has served ASN in many capacities and is currently a member of the public policy board.

He has received many awards, most notably, several “Best Doctors in America” listings, the Joel D. Kopple Award of the National Kidney Foundation, and the Medal of Excellence Award from the American Association of Kidney Patients.

Bullboard Posts